- Volpara Health Technologies (VHT) has signed its highest ever value contract which will generate US$2.15 million (A$2.96 million) over five years
- The specific customer hasn’t been disclosed, but it is a US-based diagnostic imaging provider
- Volpara will install its Patient Hub software across the customer’s network of imaging centres to provide a patient tracking platform
- The platform will allow the customer to accurately organise each patient into the appropriate personalised breast cancer screening pathway
- Company shares ended the day 2.94 per cent in the red to close at $1.15 each
Volpara Health Technologies (VHT) has signed its highest-value contract ever.
The company entered a five-year deal with an undisclosed leading US outpatient diagnostic imaging provider.
The contract is valued at US$2.15 million (A$2.96 million) which represents US$430,000 (A$592,755) of annualised recurring revenue.
Volpara will install its software across the customer’s extensive network of imaging centres which are located in 11 US states.
The Patient Hub software will provide a patient tracking platform that incorporates Volpara’s Risk and Scorecard products which are used for early detection and to manage patients at high risk of breast cancer.
Incorporating these products into the patient tracking platform will allow the customer to accurately organise each patient into the appropriate personalised breast cancer screening pathway.
Volpara’s group CEO, Ralph Highnam, was pleased to have secured such a significant contract.
“We are experiencing tremendous momentum for our platform in the market as we bring together best-of-breed patient tracking, risk assessment and density scoring to allow our customers to provide their patients with the individualised care they deserve,” Dr Highnam said.
Company shares ended the day 2.94 per cent in the red to close at $1.15 each.